Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma

Journal of Urology

Volumn 158, Issue 6, 1997, Pages 2278-2283

  Matsushima, Hisashi ^a   Kitamura, Tadaichi ^a   Goto, Toshitaka ^a   Hosaka, Yoshio ^a   Homma, Yukio ^a   Kawabe, Kazuki ^a  

^a NONE

Author keywords

bcl 2; Immunohistochemistry; p53; Prognosis; Prostatic carcinoma

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0030829938     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68235-1     Document Type: Article

References (30)

1. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
2. Colombel, M., Symmans, F., Gil, S., O'Toole, K., Chopin, D., Benson, M., Olsson, C., Korsmeyer, S. and Buttyan, R.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol., 143: 390, 1993.
3. Cleary, M. and Sklar, J.: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA, 82: 7439, 1985.
4. Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. and Croce, C.: The t(14;18) chromosomal translocation involved in B-cell neoplasms results from mistakes in VDJ joining. Science, 229: 1390, 1985.
5. Matsushima, H., Hosaka, Y., Suzuki, M., Mizutani, T., Ishizuka, H. and Kawabe, K.: bcl-2 expression in prostate cancer and its relationship to cell cycle and prognosis. Int. J. Urol., 3: 113, 1996.
6. Dinjens, W. N. M., van der Weiden, M. M., Schroeder, F. H., Bosman, F. T. and Trapman, J.: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer, 56: 630, 1994.
7. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Allred, D. C.: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369, 1993.
8. Konishi, N., Hiasa, Y., Hayashi, I., Matsuda, H., Tsuzuki, T., Ming, T., Kitahori, Y., Shiraishi, T., Yatani, R. and Shimazaki, J.: p53 mutations occur in clinical, but not in latent, human prostate carcinoma. Jpn. J. Cancer Res., 86: 57, 1995.
9. Bruner, J. M., Connelly, J. H. and Saya, H.: p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod. Pathol., 6: 189, 1993.
10. Kallakury, B. V. S., Figge, J., Ross, J. S., Fisher, H. A. G., Figge, H. L. and Jennings, T. A.: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum. Pathol., 25: 92, 1994.
11. Shurbaji, M. S., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol., 26: 106, 1995.
12. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blohlinger, A., Gasser, T. C. and Mihatsch, M. J.: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol., 148: 1557, 1996.
13. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nicholas, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 protein accumulation and gene mutation in the progression of prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
14. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T. and Thompson, T. C.: Association of p53 with metastatic prostate cancer. Clin. Cancer Res., 1: 1111, 1995.
15. Visakorpi, T., Kallioniemi, O.-P., Heikkinen, A., Koivula, T. and Isola, J.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883, 1992.
16. Bauer, J. J., Sesterhenn, I. A., Mostofi, K. F., McLeod, D. G., Srivastava, S. and Moul, J. W.: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295, 1995.
17. Foster, C. S., McLoughlin, J., Bashir, I. and Abel, P. D.: Markers of the metastatic phenotype in prostate cancer. Hum. Pathol., 23: 381, 1992.
18. Nakamura, S., Akazawa, K., Kinukawa, N., Yao, T. and Tsuneyoshi, M.: Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum. Pathol., 27: 225, 1996.
19. Gorczyca, W., Markiewski, M., Kram, A., Tuziak, T. and Domagala, W.: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchow Arch., 426: 229, 1995.
20. Pilotti, S., Collini, P., Rilke, F., Gattoretti, G., Bo, R. D. and Pierotti, M. A.: Bcl-2 expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. Pathol., 172: 337, 1994.
21. Lu, Q.-L., Abel, P., Foster, C. S. and Lanani, E.-N.: bcl-2: Role in epithelial differentiation and oncogenesis. Hum. Pathol., 27: 102, 1996.
22. Haldar, S., Negrini, M., Monne, M., Sabbioni, S. and Croce, C. M.: Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095, 1994.
23. Raffo, A. J., Perlman, H., Chen, M.-W., Day, M. L., Streitman, J. S. and Buttyan, R.: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438, 1995.
24. Castle, V. P., Heidelberger, K. P., Bromberg, J., Ou, X., Dole, M. and Nunez, G.: Expression of apoptosis-suppressing protein Bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol., 143: 1543, 1993.
25. Campos, L., Roualult, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Arhimbaud, E., Magaud, J. P. and Guyotat, D.: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor prognosis to chemotherapy. Blood, 18: 3091, 1993.
26. Joensuu, H., Pylkkäen, L. and Toikkanen, S.: Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191, 1994.
27. Viale, G., Roncalli, M., Grimelius, L., Graziani, D., Wilander, E., Johansson, H., Bergholm, U. and Coggi, G.: Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum. Pathol., 26: 945, 1995.
28. Bilim, V., Tomita, Y., Kawasaki, T., Katagiri, A., Imai, T., Takeda, M. and Takahashi, K.: Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J. Natl. Cancer Inst., 88: 686, 1996.
29. Glick, S. H., Howell, L. P. and White, R. W. D.: Relationship of p53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. J. Urol., 155: 1754, 1996.
30. Bhargava, V., Kell, D. L., van de Rijn, M. and Warnke, R. A.: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am. J. Pathol., 145: 535, 1994.